Please ensure Javascript is enabled for purposes of website accessibility

Castlight Health Jumped 12.1% in August -- Here's Why

By Brian Feroldi – Sep 9, 2016 at 10:42AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A better-than-expected second-quarter earnings report sends shares soaring.

Image source: Getty Images.

What happened

Investors in Castlight Health (CSLT), a cloud-based software company focused on employee health, had an August to smile about. Shares moved 12% higher during the month in response to better-than-expected second-quarter results, according to data from S&P Global Market Intelligence.

CSLT Chart

CSLT data by YCharts.

So what

The report looked solid all around. Revenue increased by 27% to $23.6 million, which was higher than analysts were expecting. Gross margins shot up to 62.1% on a non-GAAP basis, up 800 basis points over the year-ago period. Non-GAAP net loss fell to $10.5 million, or $0.11 per share, which was much better than the $0.13 net loss that analysts had predicted. 

Management credits the company's strong growth in part to its recently announced strategic collaborations with Anthem and SAP, which have given its platform a great deal of credibility. Castlight appears to have done a great job recently of leveraging that credibility into new clients. During the quarter, it signed up a handful of new giant customers that included Roche's Genetech division and Caterpillar.

With the company successfully growing its top line and signs emerging that the business is starting to scale, it's easy to see why its shares rallied in August.

Now what

Management is currently projecting that full-year revenue will land between $99 million to $102 million, which represents growth of 31% to 35%. That's consistent with the outlook provided in its first-quarter report.  On the bottom line, the company is now calling for a non-GAAP EPS loss of $0.40 to $0.42 for the year, which is a penny better than its prior outlook. 

These results are certainly encouraging, but given that Castlight health is still losing millions each quarter and has been a horrific long-term investment, I'll be looking for it to string together a few more successful quarters before considering its shares a buy. 

Brian Feroldi has no position in any stocks mentioned. Like this article? Follow him on Twitter where he goes by the handle @Longtermmindset or connect with him on LinkedIn to see more articles like this.

The Motley Fool recommends Anthem. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Castlight Health Stock Quote
Castlight Health

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.